Genetic testing in cardiovascular diseases

Current Opinion in Cardiology

Volumn 29, Issue 3, 2014, Pages 235-240

  Arndt, Anne Karin ^a,b   MacRae, Calum A ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cardiovascular disease; congenital heart disease; gene testing; genetics; genomics

Indexed keywords

AORTA ANEURYSM; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHANGE MANAGEMENT; CLINICAL DECISION MAKING; COMMUNITY; CONGESTIVE CARDIOMYOPATHY; COPY NUMBER VARIATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; EPIDEMIOLOGY; EQUIPOISE; EXOME; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETICS; GENOMICS; GENOTYPE; HEART ARRHYTHMIA; HEART PROARRHYTHMIA; HISTONE MODIFICATION; HUMAN; HYPERCHOLESTEROLEMIA; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MENDELIAN DISEASE; MISSENSE MUTATION; MORBIDITY; MORTALITY; NULL ALLELE; OSTEOARTHRITIS; PATHOGENICITY; PHENOTYPE; PLEIOTROPY; PREVALENCE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; SOMATIC MUTATION; SUDDEN DEATH; VENTRICULAR NONCOMPACTION; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; GENE THERAPY; GENETIC PREDISPOSITION; HUMAN GENOME; ORGANIZATION AND MANAGEMENT; PROCEDURES; TRANSLATIONAL RESEARCH; TRENDS;

CYCLIC GMP DEPENDENT PROTEIN KINASE 1; DNA BINDING PROTEIN; PRDM16 PROTEIN, HUMAN; PRKG1 PROTEIN, HUMAN; SMAD2 PROTEIN; SODIUM CHANNEL NAV1.5; TRANSCRIPTION FACTOR;

CARDIOVASCULAR DISEASES; CYCLIC GMP-DEPENDENT PROTEIN KINASE TYPE I; DISEASE MANAGEMENT; DNA-BINDING PROTEINS; EXOME; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC THERAPY; GENOME, HUMAN; HUMANS; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; SMAD2 PROTEIN; TRANSCRIPTION FACTORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84899098994     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000055     Document Type: Review

References (44)

1. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012; 60:705-715.
2. MacRae CA. Closer look at genetic testing in long-QT syndrome: will DNA diagnostics ever be enough? Circulation 2009; 120:1745-1748.
3. Deo RC, MacRae CA. Clinical screening and genetic testing. Clin Lab Med 2010; 30:775-784.
4. Ho CY, MacRae CA. Defining the pathogenicity of DNA sequence variation. Circ Cardiovasc Genet 2009; 2:95-97.
5. Lee MS, Macrae CA. Revisiting risk stratification in hypertrophic cardiomyopathy: do we need to start from scratch? Heart Rhythm 2012; 9:64-65.
6. Bick AG, Flannick J, Ito K, et al. Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am J Hum Genet 2012; 91:513-519.
7. Rehm HL. Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet 2013; 14:295-300.
8. Duzkale H, Shen J, McLaughlin H, et al. A systematic approach to assessing the clinical significance of genetic variants. Clin Genet 2013; 84:453-463.
9. Thurberg BL, Fallon JT, Mitchell R, et al. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 2009; 119:2561-2567.
10. Chen R, Snyder M. Promise of personalized omics to precision medicine. Wiley Interdiscip Rev Syst Biol Med 2013; 5:73-82.
11. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 2011; 13:1077-1109.
12. Gonzaga-Jauregui C, Lupski JR, Gibbs RA. Human genome sequencing in health and disease. Ann Rev Med 2012; 63:35-61.
13. Crotti L, Johnson CN, Graf E, et al. Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation 2013; 127:1009-1017.
14. Nyegaard M, Overgaard MT, Sondergaard MT, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet 2012; 91:703-712.
15. Zaidi S, Choi M, Wakimoto H, et al. De novo mutations in histone-modifying genes in congenital heart disease. Nature 2013; 498:220-223.
16. Wang X, Wang J, Zhao P, et al. Familial congenital heart disease: data collection and preliminary analysis. Cardiol Young 2013; 23:394-399.
17. Arndt AK, Schafer S, Drenckhahn JD, et al. Fine mapping of the 1p36 deletion syndrome identifies mutation of PRDM16 as a cause of cardiomyopathy. Am J Hum Genet 2013; 93:67-77.
18. Guo DC, Regalado E, Casteel DE, et al. Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections. Am J Hum Genet 2013; 93:398-404.
19. van de Laar IM, Oldenburg RA, Pals G, et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 2011; 43:121-126.
20. Wischmeijer A, Van Laer L, TortoraG, et al. Thoracic aortic aneurysm in infancy in aneurysms-osteoarthritis syndrome due to a novel SMAD3 mutation: further delineation of the phenotype. Am J Med Genet A 2013; 161A:1028-1035.
21. van der Linde D, van de Laar IM, Bertoli-Avella AM, et al. Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. J Am Coll Cardiol 2012; 60:397-403.
22. van de Laar IM, van der Linde D, Oei EH, et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet 2012; 49:47-57.
23. Lindsay ME, Schepers D, Bolar NA, et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet 2012; 44:922-927.
24. Matt P, Schoenhoff F, Habashi J, et al. Circulating transforming growth factorbeta in Marfan syndrome. Circulation 2009; 120:526-532.
25. Mann SA, Castro ML, Ohanian M, et al. R222Q SCN5A mutation is associated with reversible ventricular ectopy and dilated cardiomyopathy. J Am Coll Cardiol 2012; 60:1566-1573.
26. Laurent G, Saal S, Amarouch MY, et al. Multifocal ectopic Purkinje-related premature contractions: a new SCN5A-related cardiac channelopathy. J Am Coll Cardiol 2012; 60:144-156.
27. Wilde AA, Brugada R. Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel. Circ Res 2011; 108:884-897.
28. Ritchie MD, Denny JC, Zuvich RL, et al. Genome-and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation 2013; 127:1377-1385.
29. Maron BJ, Semsarian C. Prevention of sudden death for patients with cardiomyopathies another step forward. J Am Coll Cardiol 2012; 59:501-502.
30. Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm 2012; 9:57-63.
31. Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2013; 6:533-542.
32. MacArthur DG, Balasubramanian S, Frankish A, et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science 2012; 335:823-828.
33. Erdmann J, Stark K, Esslinger UB, et al. Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature 2013; 504:432-436.
34. Crotti L, Monti MC, Insolia R, et al. NOS1AP is a genetic modifier of the long-QT syndrome. Circulation 2009; 120:1657-1663.
35. Duchatelet S, Crotti L, Peat RA, et al. Identification of a KCNQ1 polymorphism acting as a protective modifier against arrhythmic risk in long-QT syndrome. Circ Cardiovasc Genet 2013; 6:354-361.
36. Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013; 369:2283-2293.
37. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotypeguided dosing of warfarin. N Engl J Med 2013; 369:2294-2303.
38. Green RC, Farahany NA. Regulation: the FDA is overcautious on consumer genomics. Nature 2014; 505:286-287.
39. Jamal SM, Yu JH, Chong JX, et al. Practices and policies of clinical exome sequencing providers: analysis and implications. Am J Med Genet A 2013; 161A:935-950.
40. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15:565-574.
41. MacRae CA. Action and the actionability in exome variation. Circ Cardiovasc Genet 2012; 5:597-598.
42. van der Graaf A, Avis HJ, Kusters DM, et al. Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation 2011; 123:1167-1173.
43. Stein EA, Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med 2014; 65:417-431.
44. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011; 12:56-68.